You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,649,352

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,649,352 protect, and when does it expire?

Patent 9,649,352 protects KIMYRSA and ORBACTIV and is included in two NDAs.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 9,649,352

Patent landscape, scope, and claims:

Title:	High purity oritavancin and method of producing same
Abstract:	Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Inventor(s):	Rafai Far; Adel (Mount-Royal, CA), Krishna; Gopal (Parsippany, NJ), Ding; Min (Parsippany, NJ), Chemburkar; Sanjay R. (North Chicago, IL), Knable; Carl M. (North Chicago, IL), Petzel; James P. (North Chicago, IL), Pruyne; Julie J. (North Chicago, IL), Reamer; Douglas M. (North Chicago, IL)
Assignee:	THE MEDICINES COMPANY (Parsippany, NJ) ABBVIE INC. (Chicago, IL)
Application Number:	14/801,303
Patent Claim Types: see list of patent claims	Composition;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,649,352

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Melinta Therap	KIMYRSA	oritavancin diphosphate	POWDER;INTRAVENOUS	214155-001	Mar 12, 2021		RX	Yes	Yes	9,649,352	⤷ Subscribe	Y	Y			⤷ Subscribe
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes	9,649,352	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,649,352

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015289602	⤷ Subscribe
Brazil	112017000898	⤷ Subscribe
Canada	2955256	⤷ Subscribe
China	107206050	⤷ Subscribe
Eurasian Patent Organization	201700019	⤷ Subscribe
European Patent Office	3169345	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.